A phase 1b dose-escalation study of carfilzomib in combination with thalidomide and dexamethasone in patients with relapsed/refractory systemic immunoglobulin light chain amyloidosis.

Sriram RavichandranAndrew HallMatthew JennerMamta GargBhuvan KishoreHelen LachmannJulian David GillmoreAlexandra PitchfordJamie B OughtonShameem MahmoodSajitha SachchithanthamPhilip HawkinsSarah BrownAshutosh Wechalekar

Published in: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis (2023)

weekly can be safely given with thalidomide and dexamethasone. The efficacy and tolerability profile appears comparable to other agents in relapsed AL amyloidosis. These data provide a framework for further studies of carfilzomib combinations in AL amyloidosis.

Keyphrases

multiple myeloma
open label
high dose
low dose
electronic health record
randomized controlled trial
big data
clinical trial
diffuse large b cell lymphoma
acute lymphoblastic leukemia
hodgkin lymphoma
case control
data analysis
study protocol
deep learning